Recent Press Releases
May 26, 2026
NervGen announced announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study.
May 21, 2026
NervGen announced the pricing of an underwritten public offering of securities.
May 21, 2026
NervGen reported announced that it has commenced an underwritten public offering of securities.
Phase 1b/2a CONNECT SCI Study for
Individuals with Spinal Cord Injury
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
Stay Connected
Subscribe to our mailing list to stay up to date
